Table of Contents
Introduction
Adrafinil, marketed as Olmifon, is a research chemical that is believed to be able to promote wakefulness. Originally developed by a French pharmaceutical company, Adrafinil is introduced to enhance alertness, attention, wakefulness, and mood, primarily among the elderly. Moreover, it may even potentially help individuals seeking to combat fatigue, including night workers or those needing prolonged periods of wakefulness. However, FDA does not approve Adrafinil for human consumption since it requires more in-depth research studies. For this reason, buy Adrafinil for laboratory research use only.
What is Adrafinil?
Adrafinil is a nootropic compound that could affect the central nervous system and is believed to enhance cognitive function. It is often studied to promote wakefulness and help individuals stay alert for extended periods. The potential effects of administered Adrafinil powder on cognitive function make it a popular choice among researchers who are seeking to improve mental performance.
Despite the mentioned probable health benefits, Adrafinil is not a prescription medication in the USA.
- CAS Number: 63547-13-7
- Molar Mass: 289.35 g/mol
- Chemical Formula: C15H15NO3S
- IUPAC Name: 2-benzhydrylsulfinylethanehydroxamic acid
- Also known by Synonyms Olmifon, CRL 40028, 2-[(Diphenylmethyl)sulfinyl]-N-hydroxyacetamide
Key Features
- 98% Purity
- 5g | 10g
- Sold for laboratory research purposes
How does it work?
Adrafinil, in its initial form, is inactive and needs to undergo conversion to modafinil in the liver to become active (known as a “prodrug” of modafinil). However, only a small portion of adrafinil actually converts to modafinil, while the majority remains inactive. Consequently, larger doses of adrafinil are generally needed to achieve similar effects compared to modafinil.
The biological half-life of adrafinil is short, lasting only around 1 hour. However, a portion of it gets metabolized into modafinil, which has a longer half-life of 12 to 15 hours. As a result, the effects of adrafinil can persist for several hours after consumption.
In a randomized controlled trial involving 10 elderly test subjects, it was observed that peak blood levels of adrafinil were reached approximately 1 hour after ingestion. The main effects on brain function and behavior were reported to occur approximately 2 hours after initial consumption.
Potential Benefits of Adrafinil
Below are the studies done for Adrafinil involving animals and a few human trials. An appropriate institutional review board has reviewed these studies. For animal trials, these have been evaluated by appropriate institutional animal care to ensure conformity with the Animal Welfare Act.
Cognitive Functions
Preclinical research studies conducted on older animals, specifically dogs, have suggested the potential effects of adrafinil on cognitive functions like learning and memory. However, there is limited research conducted on test subjects to validate these early findings. Two studies involving 951 test subjects, including one double-blind randomized controlled trial and one randomized controlled trial, indicated that Adrafinil may reduce forgetfulness and improve information recall. [R] [R] [R]
Mental and Physical Function
Adrafinil has shown potential to improve mental and physical function based on research studies. In a randomized controlled trial involving 548 older adults with attention and memory problems, adrafinil was found to increase their ability to perform daily activities. Another study with 70 depressed older adults compared Adrafinil to an antidepressant and reported improvements in the slowness of thought and movement, known as psychomotor impairment. [R] [R] [R]
However, it’s important to consider early evidence from animal studies that suggests adrafinil may have a general stimulating effect on movement and exploratory behavior in mice, rats, monkeys, and dogs. [R] [R] [R]
Narcolepsy and Other Fatigue Disorders
Adrafinil has the potential to be used for conditions like narcolepsy and work-shift sleep disorder, which are currently treated with modafinil, a related drug. Adrafinil is converted to modafinil in the body, which is why it could theoretically have similar effects. However, adrafinil is not widely prescribed by doctors for these conditions due to its limited research compared to modafinil. [R]
Adrafinil is also less potent than modafinil, so higher doses would be needed to achieve similar effects, which may carry more risks. As a result, it is unlikely that adrafinil will receive medical approval for these uses in the near future. [R]
Awareness and Focus
Several studies, including two double-blind randomized controlled trials and one randomized controlled trial, have reported that adrafinil can potentially enhance awareness and focus in older test subjects. These studies demonstrated an increase in attention, concentration, and vigilance among participants who took Adrafinil. Additionally, another study involving 10 elderly test subjects found that adrafinil decreased brain activity associated with sleep, such as slow-wave delta and theta wavelengths, while increasing brain activity associated with being engaged in the present, represented by alpha wavelengths. [R] [R]
Depression
Early research suggested the potential of adrafinil in treating depression. One study conducted in 1999 examined adrafinil’s effects on 70 elderly test subjects with a milder form of depression. After two months of treatment, adrafinil showed improvement in depression symptom severity scores compared to a placebo. However, it is important to note that the improvement was mainly observed in psychomotor symptoms of depression, such as slowed movements and decreased energy, rather than overall mood improvement. [R]
Limited follow-up studies have been conducted since then, but some suggest that adrafinil may partially reduce depression symptoms. Another study compared adrafinil to the antidepressant clomipramine in 70 depressed patients and found that adrafinil was better tolerated with fewer side effects. [R]
Precautions to Consider
When researching the use of Adrafinil, it is essential to take certain precautions. Here are some precautions to keep in mind:
Observe best practices for studying research chemicals. Studying research chemicals requires a responsible and informed approach to ensure safety and meaningful scientific exploration. Research chemicals, also known as designer drugs or experimental compounds, are substances synthesized for scientific investigation or exploration of their properties.
Follow recommended dosage: adhere to the recommended dosage instructions outlined on the product label. Avoid exceeding the suggested dose to minimize the risk of potential adverse effects among test subjects.
Potential Side Effects
Adrafinil is generally well-tolerated, according to most studies. However, a small number of test subjects have reported certain side effects, such as increased stress, aggression, nausea, an irregular heartbeat, dry mouth, stomach pain, and skin irritation.
In one case, a clinical subject experienced abnormal facial movements after taking a daily dose of 900 mg of adrafinil for 10 months. This symptom did not improve even after 4 months of discontinuing Adrafinil, but it subsided after the subject started taking a medication that lowers dopamine levels.
Concerns have been raised about the potential impact of adrafinil on liver health since it is metabolized into modafinil in the liver.
Conclusion
In conclusion, adrafinil shows promising potential based on clinical research in various areas. It has been associated with positive effects on cognitive functions, such as reducing forgetfulness and improving information recall, although more research on test subjects is needed to confirm these findings.
Adrafinil has demonstrated benefits for mental and physical function, as seen in studies involving older test subjects with attention and memory problems. It has shown improvements in daily activity performance and psychomotor impairment compared to an antidepressant.
While early evidence from animal studies suggests a stimulating effect on movement and exploratory behavior, further research is required to understand the specific effects of adrafinil on cognition and behavior in humans.
Regarding narcolepsy and fatigue-related disorders, adrafinil holds potential as a treatment option due to its conversion to modafinil in the body. However, its limited research and lower potency compared to modafinil currently hinder widespread medical use for these conditions.
Studies have also indicated that adrafinil can enhance awareness and focus, as evidenced by increased attention, concentration, and vigilance in older test subjects. Brain activity patterns associated with sleep and present engagement have shown positive changes with Adrafinil.
While early studies have suggested adrafinil’s potential in treating depression, more comprehensive research is needed to establish its efficacy and determine its role in addressing depressive symptoms.
It is crucial to note that the information provided here is based on available laboratory research and should not constitute medical advice. Adrafinil is classified as a research chemical and falls under the category of nootropics. Any decision regarding its use should be made in consultation with healthcare professionals, considering the test subjects’ circumstances and needs.
Disclaimer:
Please take note of the scientific applications of this product and carefully read our Terms and Conditions before purchasing RCD.bio. By completing your order and submitting payment, you agree to abide by the terms and conditions of our company. Please be aware that the product packaging may differ slightly from the images displayed on our website.
If, for any reason, you are not completely satisfied with the product you receive, please contact us at support@rcdbio.co. Our team is dedicated to ensuring satisfaction among our customers.
Please note: All products offered by RCD.bio are strictly intended for laboratory and research purposes only. They are not intended for use on animals or humans.
